These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2502156)

  • 21. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
    Zhang Z; Li S; Gu Y; Xia N
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B cell activation and HIV infection: protective or potentially detrimental response?
    Amadori A; Chieco-Bianchi L
    Int Rev Immunol; 1992; 9(1):15-24. PubMed ID: 1484267
    [No Abstract]   [Full Text] [Related]  

  • 23. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The usefulness of HIV serology in the follow up of vertical transmission of AIDS].
    Tuset Ruiz C; León Sebastia P; Elorza Arizmendi J; Tuset Ruiz L; Vidal Rico S; Tacons Mateu J
    An Esp Pediatr; 1990 Nov; 33(5):424-8. PubMed ID: 2096755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there any room for therapeutic vaccination against the HIV-1/AIDS?
    Iglesias E
    Hum Vaccin Immunother; 2013 Jul; 9(7):1539-44. PubMed ID: 23571171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
    Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
    Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The chemistry of site-directed serology for HIV infections.
    Norrby E; Biberfeld G; Johnson PR; Parks DE; Houghten RA; Lerner RA
    AIDS Res Hum Retroviruses; 1989 Oct; 5(5):487-93. PubMed ID: 2480152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
    Boudet F; Girard M; Theze J; Zouali M
    Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AIDS. Do antibodies enhance the infection of cells by HIV?
    Bolognesi DP
    Nature; 1989 Aug; 340(6233):431-2. PubMed ID: 2787895
    [No Abstract]   [Full Text] [Related]  

  • 30. Broad HIV-1 neutralization mediated by CD4-binding site antibodies.
    Li Y; Migueles SA; Welcher B; Svehla K; Phogat A; Louder MK; Wu X; Shaw GM; Connors M; Wyatt RT; Mascola JR
    Nat Med; 2007 Sep; 13(9):1032-4. PubMed ID: 17721546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [HIV-1 and HIV-2 coinfection or cross reaction?].
    Calderón E; Corzo JE; Pineda JA; Leal M
    Med Clin (Barc); 1990 Mar; 94(11):437-8. PubMed ID: 2377017
    [No Abstract]   [Full Text] [Related]  

  • 32. [Diagnostic value of antibodies against HIV-1 proteins in seropositive drug addicts tested by the western blotting method].
    Swiderska H; Kalinowska B
    Przegl Epidemiol; 1992; 46(1-2):19-25. PubMed ID: 1475386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The relevance of phenotypic markers for progression in AIDS in HIV-1+ children].
    Zugun F; Sfartz S; Carasevici E
    Bacteriol Virusol Parazitol Epidemiol; 1995; 40(3-4):253-6. PubMed ID: 8640013
    [No Abstract]   [Full Text] [Related]  

  • 34. Measuring vaccine-induced HIV neutralization: report of a workshop.
    Hanson CV
    AIDS Res Hum Retroviruses; 1994 Jun; 10(6):645-8. PubMed ID: 8074928
    [No Abstract]   [Full Text] [Related]  

  • 35. [Repeated passive immunotherapy delays AIDS progression].
    Paris KA
    Fortschr Med; 1995 May; 113(14):13. PubMed ID: 7607586
    [No Abstract]   [Full Text] [Related]  

  • 36. [Epidemiology of HIV infection and the organization of anti- epidemiologic measures in the USSR 1987-1991].
    Pokrovskiĭ VV; Savchenko IG; Suvorova ZK; Buravtsova EV; Pankova GIu; Arzamastsev VP; Bochkov AD
    Vestn Ross Akad Med Nauk; 1992; (9-10):8-11. PubMed ID: 1283725
    [No Abstract]   [Full Text] [Related]  

  • 37. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection.
    Sawyer LA; Katzenstein DA; Hendry RM; Boone EJ; Vujcic LK; Williams CC; Zeger SL; Saah AJ; Rinaldo CR; Phair JP
    AIDS Res Hum Retroviruses; 1990 Mar; 6(3):341-56. PubMed ID: 1971182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Peptides from the principal neutralizing and CD4-binding domain: similar immunoreactive properties and structure pattern].
    Meshcheriakova DV; Andreev SM; Sidorova MV; Vafina MG; Az'muko AA; Petrukhina AO; Khaitov RM
    Vestn Ross Akad Med Nauk; 1992; (9-10):47-52. PubMed ID: 1283721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative analysis of gp41 antigens by enzyme-linked immunosorbent assays for detecting antibodies to human immunodeficiency virus type 1.
    Zweig M; Bladen SV; Dubois GC; Samuel KP; Showalter SD; Papas TS
    AIDS Res Hum Retroviruses; 1988 Dec; 4(6):487-92. PubMed ID: 3265329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human immunodeficiency virus 1: predominance of a group-specific neutralizing epitope that persists despite genetic variation.
    Dis Markers; 1990; 8(2):105-7. PubMed ID: 1696869
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.